NL-OMON42207已完成2 期
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID*SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA. - Vocals
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Patients, age 18-75 years at the time of informed consent
- •- Severe asthma despite intensive follow-up by an asthma specialist for at least 6 months prior to Visit 1
- •- Baseline forced expiratory volume in 1 second (FEV1) * 40% of predicted prior to randomization
- •-Receiving high doses of inhaled glucocorticosteroids at a total daily dose of * 1500 mcg beclomethasone dipropionate daily or equivalent and long-acting beta-adrenoceptor agonist (LABA), with or without an additional controller, for at least 3 months prior to Visit 1;
- •- Chronic treatment with maintenance oral corticosteroids (prednisone/prednisolone) for at least 6 months prior to Visit 1
- •- Assessment to ensure diagnosis of refractory asthma and oral corticosteroid dependence on minimal effective or maximum tolerated dose prior to visit 1 with compliance
排除标准
- •- History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
- •- Asthma exacerbation within 28 days prior to Visit 1 or during screening (prior to Visit 3
- •- For adults: Active tuberculosis requiring treatment within the 12 months prior to visit 1
- •- Evidence of acute or chronic hepatitis or known liver cirrhosis
- •- Known current malignancy or current evaluation for a potential malignancy
- •- History of interstitial lung disease, chronic obstructive pulmonary disease, or other clinically significant lung disease other than asthma
- •- Infection requiring hospital admission or requiring treatment with IV or IM antibiotics within 4 weeks prior to visit 1 or during screening
- •- Upper or lower respiratory tract infection within 4 weeks prior to visit 1 or during screening
- •- Active parasitic infection or Listeria monocytogenes infection within 6 months prior to visit 1 or during screening
- •- Current smoker or former smoker with a smoking history of >15 pack-years
- •- Current use of an immunomodulatory/immunosuppressive therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to visit 1
- •- Use of a licensed or investigational monoclonal antibody other than anti IL-13 or anti IL-4/IL-13, including, but not limited to, omalizumab, anti IL-5, or anti IL-17, within 6 months or 5 drug half-lives (whichever is longer) prior to visit 1
- •- Receipt of a live, attenuated vaccine within the 4 weeks prior to visit 1, during screening or anticipation of receipt of alive, attenuated vaccine throughout the study
研究者
相似试验
进行中（未招募）
1 期
A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis.IDIOPATHIC PULMONARY FIBROSISEUCTR2013-001163-24-PLF. Hoffmann-La Roche Ltd480
进行中（未招募）
不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - N/AMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDChronic Obstructive Pulmonary DiseaseEUCTR2007-004466-41-HUPfizer Ltd, Ramsgate Road, Sandwich, Kent640
招募中
2 期
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS, INCLUDING AN EVALUATION OF OPEN LABEL SAFETY AND PK IN A COHORT OF PEDIATRIC PATIENTS (AGED 5 to < 12).11 NULLN118 Other chronic tubulo-interstitial nephritisOther chronic tubulo-interstitial nephritisN118PER-051-21F. HOFFMANN-LA ROCHE LTD.2
进行中（未招募）
1 期
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington’s DiseaseHuntington's disease (HD)MedDRA version: 20.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2022-001991-32-PTF.Hoffmann-La Roche Ltd300
进行中（未招募）
不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LEBRIKIZUMAB (MILR1444A)IN ADULT PATIENTS WITH ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROIDS. - MILLYAsthma in patients who are inadequately controlled by inhaled corticosteroidsMedDRA version: 9.1Level: PTClassification code 10003553Term: AsthmaEUCTR2009-010359-28-CZGenentech, Inc210